ACADIA Pharmaceuticals (ACAD) Competitors $22.20 -0.10 (-0.45%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$22.11 -0.09 (-0.40%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences ACADIA Pharmaceuticals (NASDAQ:ACAD) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Which has more volatility & risk, ACAD or ITCI? ACADIA Pharmaceuticals has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Do analysts rate ACAD or ITCI? ACADIA Pharmaceuticals currently has a consensus target price of $26.79, indicating a potential upside of 20.66%. Intra-Cellular Therapies has a consensus target price of $109.70, indicating a potential downside of 16.81%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.69Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is ACAD or ITCI more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to Intra-Cellular Therapies' net margin of -14.07%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets ACADIA Pharmaceuticals13.83% 25.83% 14.71% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do institutionals and insiders believe in ACAD or ITCI? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, ACAD or ITCI? ACADIA Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioACADIA Pharmaceuticals$996.28M3.73-$61.29M$1.3716.20Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the media favor ACAD or ITCI? In the previous week, ACADIA Pharmaceuticals had 28 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 28 mentions for ACADIA Pharmaceuticals and 0 mentions for Intra-Cellular Therapies. ACADIA Pharmaceuticals' average media sentiment score of 0.89 beat Intra-Cellular Therapies' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ACADIA Pharmaceuticals Positive Intra-Cellular Therapies Neutral Does the MarketBeat Community favor ACAD or ITCI? ACADIA Pharmaceuticals received 386 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 72.99% of users gave ACADIA Pharmaceuticals an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformACADIA PharmaceuticalsOutperform Votes90872.99% Underperform Votes33627.01% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% SummaryACADIA Pharmaceuticals beats Intra-Cellular Therapies on 17 of the 19 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.72B$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio28.468.7927.2120.17Price / Sales3.73263.51414.99161.94Price / CashN/A65.8538.2534.64Price / Book8.446.677.124.72Net Income-$61.29M$143.49M$3.23B$247.80M7 Day Performance1.98%5.15%3.80%2.76%1 Month Performance27.29%15.43%13.40%9.71%1 Year Performance47.70%6.02%32.04%14.51% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals3.468 of 5 stars$22.20-0.4%$26.79+20.7%+49.2%$3.72B$996.28M28.46510Trending NewsAnalyst RevisionITCIIntra-Cellular Therapies0.9031 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.285 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics3.0215 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Analyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.2409 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.2894 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4393 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.2307 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.1584 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.9085 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640Positive NewsGap UpHigh Trading VolumeROIVRoivant Sciences2.3799 of 5 stars$11.17+1.6%$17.50+56.7%+7.5%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
